Insempra Announces First Fermentation-Based Functional Ingredient for Consumer Goods
Insempra, a biology-powered company enabling businesses to make superior products with nature, today announces that it has launched its first functional ingredient, a biotechnologically produced, 100% natural alpha-Ionone flavour and fragrance ingredient for food and beauty market applications.
Insempra has partnered with leading natural aroma ingredients manufacturer and distributor Axxence Aromatic GmbH to market the product to food and beauty manufacturers globally. Under the terms of the agreement, Axxence has been distributing the product to customers since the beginning of 2023.
Alpha-Ionone is an aroma compound found in a variety of essential oils, mainly derived from natural sources such as raspberries, almonds, and blackberries. In contrast to chemically manufactured, racemic alpha-Ionone aromas, Insempra’s natural product has a more defined and purer aroma achieved by selectively producing only the desired enantiomer, (R)-alpha-Ionone, resulting in a uniquely superior, deep and fresh violet and raspberry aroma which can be applied as a high-quality flavour and fragrance to a variety of consumer products.
Insempra’s fermentation-based alpha-Ionone, initially developed by Phytowelt Green Technologies GmbH, is an EU-natural certified, vegan, food-grade ingredient. Insempra’s biotechnology platform capabilities combined with Axxence's market access ensures consistently high product quality for flavour and fragrance manufacturers.
"With the launch of this superior alpha-Ionone aroma, Insempra is demonstrating its unique approach to technology onboarding, scaling and rapid go-to-market capabilities in the delivery of the next generation of sustainable, biotechnologically produced functional ingredients,” says Insempra CEO and founder Jens Klein. “By identifying a market-driven need for a more sustainable ingredient solution and finding the right partners, we are able to deliver a 100% natural, fermentation-based functional ingredient for food and beauty applications that is truly superior to natural or synthetic alternatives.”
“We are delighted with our cooperation with Insempra,” adds Ron Honing, CEO of Axxence. “We have successfully introduced (R)-alpha-Ionone to the market. Now with the support of Insempra we will enter a new avenue that will improve the speed to market and a balanced cost in use. Together we will explore the pathway of Natural aroma ingredients and will bring more sustainable ingredient solutions that clearly deserve the EU Natural label.”
With consumer demand rising for products with 100% natural ingredients that are healthy for humans as well as the planet, Insempra’s mission is to collaborate with nature to develop sustainable and scalable ingredient solutions for broad market applications.
The production of raspberry aroma by farming would require more than a hundred tonnes of raspberries, which translates to approximately 40 football fields of cultivated acreage – a highly unsustainable use of land that is equally disproportionate in its output. The alternatives to naturally derived alpha-Ionone are chemically manufactured aroma replicas which are currently broadly used in consumer goods. The trend towards natural ingredients is driving the biotechnological production of aromas which in this example could be done with just one production run on a small-scale fermenter compared to the exorbitant land use if extracted from nature.
About Insempra
Insempra is a biology-powered company enabling businesses to make superior products with nature. We combine bioscience and technology to grow matter for new and better products.
For too long, businesses have relied on chemical industrialization processes and petrochemicals, depleting our planet’s limited resources. That’s why we are committed to drive the regenerative revolution to manufacture at scale in collaboration with nature.
Led by a hand-picked team of biologists, technologists, and entrepreneurs with rebel hearts, Insempra is here to create a new school of thought and collective action. The time to restore the balance between people and the planet is now. We don't wait for change. We do what needs to be done to grow a better future.
Learn more about Insempra at insempra.bio
About Axxence
Axxence is a leading manufacturer and supplier of natural aroma ingredients for the global Flavour and Fragrance (“F&F”) industry. Today, Axxence has around 110 employees. Its more than 250 natural aroma product solutions are sold in over 35 countries to more than 240 customers including the world’s largest F&F companies. Axxence is headquartered in Emmerich, Germany, and operates two manufacturing plants in Slovakia. Since 2021, the majority of the company is owned by the Caption Group based in Berlin, Germany.
Learn more about Axxence at axxence.de
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230403005773/en/
Contact information
FTI Consulting
Ann Bartling / Michael Trace
Tel: +44 (0)20 3727 1000
insempra@fticonsulting.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MRM Health Raises €55 Million Series B to Advance Best-in-Class Microbiome-Based Biotherapeutic Product Pipeline4.9.2025 08:00:00 EEST | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced the successful closing of a €55 million (US$64 million) Series B financing round. The round was led by French pharmaceutical group Biocodex and included strong participation from German-based ATHOS, as well as new investor BNP Paribas Fortis Private Equity and existing investors SFPIM, Ackermans & van Haaren (AvH), OMX Europe Venture Fund (OMX), Qbic II and VIB. Validation of Leadership Position in Microbiome-Based Therapeutics Proceeds will enable MRM Health to complete a Phase 2b clinical trial for its lead program MH002 in patients suffering from mild-to-moderate ulcerative colitis. MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD), with positive clinical da
Abbove Unveils “Mia”: Opening a New Chapter in Digital Wealth Planning in Europe4.9.2025 07:00:00 EEST | Press release
Abbove, the European platform for collaborative and family-centered wealth planning, announces today the launch of Mia, its new artificial intelligence agent. Used by more than 1,100 advisors and deployed to over 37,000 families across Europe, Abbove takes a major step forward in its mission to reimagine the wealth advisory experience in the digital age. Designed to enhance the capabilities of wealth advisors, family officers, and financial experts, Mia acts as an intelligent co-pilot. It simplifies the reading and analysis of complex estate documents, automatically extracts key information, and assists users in the understanding, enrichment, and structuring of wealth data. “The launch of Mia opens an entirely new functional AI vertical on our platform, unlocking near-infinite possibilities for future development. It’s a key milestone that brings us closer to our ambition of becoming the leading pan-European wealth planning platform.” — Guillaume Desclée, Founder & CEO of Abbove Native
Biocytogen Enters into Agreement with Merck, KGaA, Darmstadt, Germany to Advance Antibody-Conjugated Lipid-Based Delivery Solutions4.9.2025 03:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies and Merck KGaA, Darmstadt, Germany, a leading science and technology company, have entered into an evaluation and option agreement to advance the development of antibody-conjugated lipid-based delivery solutions for nucleic acid payloads, such as antibody-conjugated lipid nanoparticle (LNP). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250903434045/en/ Under the terms of the agreement, Biocytogen will provide proprietary, fully human antibodies derived from its RenMice® platform for evaluation in Merck KGaA, Darmstadt, Germany’s antibody-conjugated LNP services. Merck KGaA, Darmstadt, Germany has been granted an exclusive option to acquire rights to selected antibody assets in return for fees and royalties on sales and su
OpZira, Inc. Launches to Advance Ophthalmic Diagnostics with Innovative Medical Device Portfolio3.9.2025 20:23:00 EEST | Press release
OpZira™, Inc., a forward-thinking ophthalmic medical device company founded on a legacy of research excellence, today announced its official formation. OpZira is dedicated to delivering innovative technologies that enhance the detection and monitoring of ocular disease, empowering clinicians with advanced diagnostic tools. OpZira’s creation follows Alcon’s acquisition of LumiThera (https://www.alcon.com/media-release/alcon-completes-acquisition-lumithera/) and its innovative Valeda® Light Delivery System, the first and only FDA-authorized treatment for dry age-related macular degeneration (AMD). As part of the transaction, LumiThera’s diagnostic product lines were spun off to LumiThera shareholders, leading to the establishment of OpZira, Inc. OpZira’s product portfolio includes: AdaptDx Pro® – A wearable dark adaptometer that leverages AI to ensure a consistent patient experience. Impaired dark adaptation speed, a key early indicator of rod-mediated dysfunction, is often among the fir
BTG Bioliquids and NanosTech Partner to Deliver End-to-End Advanced Biofuels Solution3.9.2025 19:19:00 EEST | Press release
BTG Bioliquids BV (BTL), a Netherlands-based leader in fast pyrolysis technology, and NanosTech Technology & Innovations Ltd. (NanosTech), a Canada-based catalyst development and manufacturing company, have signed a Memorandum of Understanding (MOU) to deliver a fully integrated solution to produce advanced, drop-in biofuels. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250903698730/en/ The partnership combines BTL’s proven fast pyrolysis technology, which converts sustainable biomass into bio-oil, with NanosTech’s proprietary Aquaprocessing (AQP) platform, which upgrades even the most challenging bio-oils into refinery-ready feedstocks to produce fuels such as sustainable aviation fuel (SAF), renewable diesel, and marine fuels. The two companies are now actively collaborating to determine the location in Canada and Europe for the new 500-barrel-per-day modular biorefinery system. This system can be deployed near the feeds
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom